56 studies found for:    Open Studies | "Unrelated Donors"
Show Display Options
Rank Status Study
1 Recruiting Unrelated Donor Stem Cell Transplantation
Conditions: Severe Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Syndromes;   Chronic Myelogenous Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Large Granulocytic Leukemia
Intervention: Procedure: Allogeneic transplantation
2 Recruiting Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Conditions: Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
Interventions: Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
3 Recruiting The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients
Conditions: Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS)
Interventions: Biological: Haplo-Cord Transplant;   Procedure: Matched Unrelated Donor Transplant
4 Recruiting Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies
Conditions: Leukemia;   Myelodysplastic Syndrome;   Lymphoma
Interventions: Device: CliniMACS Fractionation system (Arm A);   Device: CliniMACS Fractionation system (Arm B)
5 Recruiting Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Conditions: Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: Fludarabine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total body irradiation;   Drug: Sirolimus
6 Recruiting Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Condition: Healthy
Intervention: Drug: Filgrastim
7 Not yet recruiting HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Conditions: Myelodysplastic Syndrome (MDS);   Chronic Lymphocytic Leukemia (CLL);   Chemotherapy-sensitive Lymphoma;   Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma;   Acute Myelogenous Leukemia (AML);   Acute Biphenotypic Leukemia (ABL);   Acute Undifferentiated Leukemia (AUL)
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5;   Radiation: Total Body Irradiation (TBI) 200cGy on Day -1;   Procedure: Infusion of non-T-cell depleted bone marrow on Day 0;   Drug: Busulfan;   Drug: Cyclophosphamide 50mg/kg/day IV on Days -2,-1;   Drug: Cyclophosphamide 50mg/kg/day IV on Days -5,-4;   Radiation: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1;   Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4;   Drug: Sirolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Drug: Pre-HCT Mesna on Days -6 and -5;   Drug: Pre-HCT Mesna on Days -2 and -1;   Drug: Pre-HCT Mesna on Days -5 and -4;   Drug: Post-HCT Mesna
8 Recruiting Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)
Condition: Haematological Malignancies
Intervention: Biological: CD25/71 allodepleted donor T-cells
9 Unknown  Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
Condition: Leukemia
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Thymoglobulin;   Radiation: Total Body Irradiation
10 Recruiting Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors
Condition: Acute Myeloid Leukemia
Interventions: Drug: Transplants from 8/8-matched Unrelated donors;   Drug: Transplants from family-mismatched/haploidentical donors
11 Recruiting Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units
Condition: Hematologic Neoplasms
Intervention: Procedure: T-Cell replete haplo-transplant
12 Not yet recruiting Study of Matched Unrelated Donor T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies After Allogeneic Transplant
Conditions: Leukemia;   Myelodysplastic Syndromes;   Lymphomas;   Multiple Myeloma;   Other High-risk Hematological Malignancies
Interventions: Biological: BPX-501;   Drug: Rimiducid
13 Recruiting Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.
Conditions: Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkins Lymphoma;   Chronic Myelogenous Leukemia;   Hodgkins Lymphoma
Intervention: Other: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
14 Recruiting Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation
Condition: Acute Myeloid Leukaemia
Intervention: Biological: Partially HLA-matched unrelated donor cells
15 Recruiting Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Graft Versus Host Disease;   Lymphoblastic Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Anemia With Excess Blasts
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
16 Unknown  Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)
Condition: Aplastic Anemia
Intervention: Drug: Cyclophosphamide, Fludarabine, Thymoglobulin
17 Unknown  Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation
Condition: Paediatric Patients Affected by Haematological Malignancies and Eligible to Undergo HSCT From an Unrelated Volunteer
Intervention: Drug: ATG Fresenius
18 Recruiting Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Hematopoietic and Lymphoid Cell Neoplasm;   Indolent Non-Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Hodgkin Lymphoma;   Small Lymphocytic Lymphoma;   T-Cell Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
19 Recruiting HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Conditions: Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
Interventions: Radiation: total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Melphalan;   Drug: Fludarabine;   Drug: Clofarabine;   Procedure: (CliniMACS) T-cell depleted PBSC Transplant
20 Recruiting GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant
Conditions: Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
Intervention: Drug: Cyclophosphamide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years